SCHEMBL6935559

SCHEMBL6935559

Cn1c(NCC(C)(C)CO)nc(-c2ccncc2)c(-c2ccc(F)cc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 12/20 0.44
MAPK9 P45984 11/20 0.44
CSNK1D P48730 11/20 0.44
MAP4K4 O95819 8/20 0.44
PRKD2 Q9BZL6 8/20 0.44
MAPK8 P45983 6/20 0.44
TAOK1 Q7L7X3 6/20 0.44
MINK1 Q8N4C8 5/20 0.44
MAPK13 O15264 5/20 0.44
MAPK12 P53778 3/20 0.44
CDC42BPA Q5VT25 2/20 0.44
SLK Q9H2G2 2/20 0.44
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
LYN P07948 1/20 0.44
PRKACA P17612 1/20 0.44
PRKCI P41743 1/20 0.44
MAPK10 P53779 1/20 0.44
MAP3K10 Q02779 1/20 0.44
PRKCZ Q05513 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6934712 0.85 MAPK14 (0.47) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL7134617 0.84 MAPK14 (0.48) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6934372 0.83 MAPK14 (0.46) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6933880 0.83 MAPK14 (0.51) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6929508 0.81 CYP3A4 (0.55) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL7256233 0.81 MAPK14 (0.53) MAPK14MAPK9CSNK1DMAP4K4PRKD2
Hydrochloric Acid SCHEMBL6933616 0.80 MAPK14 (0.52) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6932796 0.80 MAPK14 (0.46) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6932108 0.79 MAPK14 (0.52) MAPK14MAPK9CSNK1DMAP4K4PRKD2
SCHEMBL6934767 0.79 MAPK14 (0.57) MAPK14MAPK9CSNK1DMAP4K4PRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1328277-C Substituted pyrimidinone and pyridinone compounds and their use AMGEN INC (US) 2007-07-25 CN disclosed
US-6649604-B2 Analgesics; antidiabetic agents; antiinflamamtory agents AMGEN INC. 2003-11-18 US disclosed
US-20030073704-A1 Substituted pyridone compounds and methods of use AMGEN INC. 2003-04-17 US disclosed
US-6420385-B1 INFLAMMATORY, PAIN AND DIABETES DISEASES, AMGEN INC. 2002-07-16 US disclosed
US-6096753-A Substituted pyrimidinone and pyridone compounds and methods of use AMGEN INC. (US) 2000-08-01 US disclosed
CN-1246857-A Substituted pyrimidinone and pyridinone compounds and their use AMGEN INC (US) 2000-03-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073704-A1 Substituted pyridone compounds and methods of use IL6, IL1B, IL1A MAPK14 1169/4885MAPK9 1247/4885CSNK1D 1761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.